Compile Data Set for Download or QSAR
Report error Found 61 of ec50 for UniProtKB: P04406
TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651577(US20240050576, Compound 59)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651568(US20240050576, Compound 50)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651567(US20240050576, Compound 49)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651569(US20240050576, Compound 51)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651570(US20240050576, Compound 52)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651561(US20240050576, Compound 42)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651559(US20240050576, Compound 40)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651558(US20240050576, Compound 39)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651557(US20240050576, Compound 38)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651556(US20240050576, Compound 36)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651555(US20240050576, Compound 35)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651553(US20240050576, Compound 31)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651576(US20240050576, Compound 58)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651579(US20240050576, Compound 62)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651590(US20240050576, Compound 99)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651594(US20240050576, Compound 103)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651536(US20240050576, Compound 8)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651593(US20240050576, Compound 102)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651540(US20240050576, Compound 13)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651548(US20240050576, Compound 24)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651542(US20240050576, Compound 17)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651543(US20240050576, Compound 19)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651580(US20240050576, Compound 63)
Affinity DataEC50: <100nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651589(US20240050576, Compound 90)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651575(US20240050576, Compound 57)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651586(US20240050576, Compound 87)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651581(US20240050576, Compound 65)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651574(US20240050576, Compound 56)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651591(US20240050576, Compound 100)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651573(US20240050576, Compound 55)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651572(US20240050576, Compound 54)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651571(US20240050576, Compound 53)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651592(US20240050576, Compound 101)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651564(US20240050576, Compound 45)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651578(US20240050576, Compound 60)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651565(US20240050576, Compound 46)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651535(US20240050576, Compound 6)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651537(US20240050576, Compound 9)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651538(US20240050576, Compound 10)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651541(US20240050576, Compound 16)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651544(US20240050576, Compound 20)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651545(US20240050576, Compound 21)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651546(US20240050576, Compound 22)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651547(US20240050576, Compound 23)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651549(US20240050576, Compound 25)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651550(US20240050576, Compound 26)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651551(US20240050576, Compound 29)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651554(US20240050576, Compound 33)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651560(US20240050576, Compound 41)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

TargetGlyceraldehyde-3-phosphate dehydrogenase(Human)
Design Therapeutics

US Patent
LigandPNGBDBM651563(US20240050576, Compound 44)
Affinity DataEC50:  300nMAssay Description:Cell culture: Cells were cultured in RPMI1640 medium+15% FBS. Cells were maintained at a density between 2e5/mL and 1e6/mL. Cells were centrifuged, r...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 61 total ) | Next | Last >>
Jump to: